Compare TENX & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENX | VRCA |
|---|---|---|
| Founded | 1967 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.8M | 88.0M |
| IPO Year | 2001 | 2018 |
| Metric | TENX | VRCA |
|---|---|---|
| Price | $1.48 | $3.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $10.29 | ★ $13.67 |
| AVG Volume (30 Days) | ★ 1.4M | 50.8K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $54.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $1.31 | $3.08 |
| 52 Week High | $19.40 | $9.82 |
| Indicator | TENX | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 35.62 | 47.48 |
| Support Level | $1.34 | $3.19 |
| Resistance Level | $2.01 | $5.94 |
| Average True Range (ATR) | 0.12 | 0.34 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 6.25 | 38.94 |
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.